We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current HYL market cap is 150.64M. The company's latest EPS is EUR -0.5493 and P/E is -9.79.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 91k | 175k | 3.1M | 2.39M | 4.21M |
| Operating Income | -5.27M | -7.05M | -10.54M | -11.64M | -15.99M |
| Net Income | -5.37M | -7.15M | -11.58M | -11.91M | -15.38M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 5.98M | 69.18M | 63.44M | 60.73M | 47.68M |
| Total Liabilities | 16.17M | 10.12M | 15.39M | 6.82M | 8.61M |
| Total Equity | -10.19M | 59.06M | 48.06M | 53.91M | 39.07M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -4.56M | -4.57M | -11.25M | -13.02M | -12.81M |
| Investing | -1.23M | -633k | -3.08M | -11.37M | 9.89M |
| Financing | 3.31M | 69.4M | -62k | 7.84M | -131k |
| Market Cap | 150.64M |
| Price to Earnings Ratio | -9.79 |
| Price to Sales Ratio | 35.75 |
| Price to Cash Ratio | 4.95 |
| Price to Book Ratio | 3.86 |
| Dividend Yield | - |
| Shares Outstanding | 28M |
| Average Volume (1 week) | 3.48k |
| Average Volume (1 Month) | 6.2k |
| 52 Week Change | -59.40% |
| 52 Week High | 13.30 |
| 52 Week Low | 2.89 |
| Spread (Intraday) | 0.18 (3.27%) |
| Company Name | Hyloris Pharmaceuticals SA |
| Address |
boulevard patience et beaujonc liege, liege 4000 |
| Website | https://www.hyloris.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
